Liver Fibrosis Clinical Trial
Official title:
A Phase 2a, Pilot, Open-Label Trial Evaluating the Safety, Tolerability and Pharmacodynamic Effects of GS-6624 in Subjects With Fibrosis of the Liver
This study will evaluate the safety and tolerability of simtuzumab (GS-6624) in patients
with fibrosis of the liver.
Up to 20 participants will be enrolled into two sequential cohorts. Cohort 1 will consist of
10 participants who will receive simtuzumab every other week for a total of 3 infusions.
Participants in Cohort 2 (10 subjects) will also receive simtuzumab every other week for a
total of 3 infusions; the dose will depend on the safety and tolerability of simtuzumab seen
in Cohort 1.
Participants from both cohorts who have completed the main study will be allowed to continue
on simtuzumab treatment for an additional extension period, and will receive up to 13
additional infusions of simtuzumab at a fixed dose of 700 mg for an additional 24 weeks.
n/a
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06308757 -
Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis
|
N/A | |
| Recruiting |
NCT06051669 -
Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US
|
||
| Completed |
NCT06244550 -
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors
|
N/A | |
| Recruiting |
NCT06098417 -
Biomarkers in the Diagnosis and Prognosis of NAFLD
|
||
| Not yet recruiting |
NCT03623360 -
Functional MRI to Determine Severity of Cirrhosis
|
||
| Recruiting |
NCT01965418 -
A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial
|
Phase 4 | |
| Not yet recruiting |
NCT01133184 -
Improved Prevention of Perinatal Hepatitis B Transmission
|
Phase 4 | |
| Completed |
NCT00043303 -
Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis
|
Phase 2 | |
| Completed |
NCT03872024 -
Performances Evaluation of New FibroScan Probes Dedicated to Morbidly Obese Patients
|
N/A | |
| Recruiting |
NCT05912179 -
Prospective Single Centre Observational Study to Compare the Diagnostic Yield of Different Modalities of Liver Biopsy
|
||
| Recruiting |
NCT04533828 -
68Ga-FAPI PET/CT in Liver Fibrosis Patients
|
Early Phase 1 | |
| Completed |
NCT04573543 -
The Role of Immune Semaphorins in NAFLD
|
||
| Recruiting |
NCT03277651 -
Noninvasive Diagnostic Platform for Liver Fibrosis and Portal Hypertension
|
N/A | |
| Completed |
NCT01707472 -
Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis
|
Phase 2 | |
| Completed |
NCT01934777 -
Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis
|
Phase 3 | |
| Completed |
NCT01988753 -
Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
|
||
| Completed |
NCT01810458 -
Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)
|
||
| Completed |
NCT02060162 -
Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa
|
||
| Completed |
NCT00049842 -
Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)
|
Phase 3 | |
| Recruiting |
NCT06063785 -
Multispectral Optoacoustic Tomography in Patients With Cystic Fibrosis
|